Cognito Therapeutics Raises $105M Series C for Alzheimer's Neurostimulation

Cognito Therapeutics, a Cambridge-based developer of non-invasive neurostimulation devices, has raised $105M in an oversubscribed Series C funding round led by Morningside Ventures, IAG Capital Partners, and Starbloom Capital. Spectris AD delivers visual and auditory 40Hz gamma stimulation via a wearable VR headset to evoke brain oscillations preserving volume and slowing decline in mild-to-moderate Alzheimer's patients. The capital funds HOPE pivotal study readout in late 2026, FDA submission, and 2027 commercialization.

Neurotech Bets Target Alzheimer's Progression

The round closes amid rising investment in non-drug Alzheimer's therapies. Sinaptica Therapeutics raised under $10M in seed funding, while NeuroEM Therapeutics secured $6M for its Series A. Cognito's at-home audiovisual approach differentiates from competitors' clinic-based magnetic or electromagnetic stimulation, addressing accessibility gaps with 85% patient adherence in OVERTURE.

500K New U.S. Cases Demand Progression Slowers

Alzheimer's therapeutics market hits $5B in 2026 amid 500K annual new U.S. diagnoses. Current drugs manage symptoms but fail to halt neurodegeneration, with high costs and side effects like ARIA limiting reach. Non-invasive devices offer disease-modifying potential without pharmaceuticals' drawbacks.

Gamma Entrainment Preserves Brain Structure

Spectris AD uses light and sound at 40Hz to induce gamma oscillations, reducing cognitive decline 76% and brain volume loss 69% versus sham in OVERTURE (n=76). Unlike Sinaptica's rTMS or NeuroEM's RF waves targeting proteins, Cognito focuses on neuroprotection via neural synchrony. HOPE pivotal trial (n=673, 70 sites) builds on this, fully enrolled without amyloid confirmation barriers.

As Gerald Chan, founder of Morningside Ventures, noted:

"Cognito represents a rare convergence of rigorous neuroscience research, clinical validation, elegant engineering, and a deep understanding of patient needs."

Repeat Investors Signal FDA Path Confidence

Morningside brings biotech neurology expertise from 400+ investments, while repeat backers IAG and Starbloom add neuroAI continuity. New entrants Apollo Health Ventures (neurodegenerative focus) and New Vintage (secondaries) indicate growth conviction post-$73M Series B. This mix validates Cognito's shift from R&D to regulatory push.

$5B Market Grows at 9% CAGR

Alzheimer's therapeutics expands from $5B in 2026 at 9% CAGR, driven by aging demographics and FDA breakthrough nods for devices like Spectris (2021). Competitors trail: Nuuron at €3.5M seed, Grey Matter Neurosciences $14M seed. Federal $100M+ AD funding and post-amyloid shifts favor non-invasive options.

MIT Founders Invent Core Technology

Co-founders Ed Boyden (MIT neurotechnology professor, optogenetics pioneer) and Li-Huei Tsai (Picower Institute director) discovered gamma entrainment's Alzheimer's benefits in MIT labs. Their IP underpins Spectris, with Boyden's neurotech startups like Elemind adding hardware credibility. Recent exec hires (CEO Christian Howell, CCO Deanna Angello) bolster commercialization.

HOPE Data Drives 2027 Launch

Topline HOPE results arrive end-2026, enabling FDA submission and Spectris launch as first at-home neuroprotective therapy. WVU Rockefeller partnership launches Brain Health Collaboratory for expansion into Parkinson's via AI-real-world data.